It is time to reconsider leukoreduction of whole blood for use in patients with life‐threatening hemorrhage
Year: 2024
Type: article
Abstract: PCS consults for Hemanext, Cerus, is on the scientific advisory board for Haima and Octapharma, and is a co-founder and chief medical officer for Kalocyte. EMB reports personal fees and non-financial support from Grifols, Abbott, UpToDate, Tegus, and Health Advances outside of the submitted work. EMB is a co-investigator on a US government-funded clinical trial evaluating Mirasol Pathogen Reduction Technology. CSC is on the scientific advisory board of Fresenius-Kabi and is a consultant for Quidel OrthoClinical. MHY is on the scientific advisory board for Hemanext and has given paid lectures for Terumo BCT and Grifols. The remaining authors declare no conflict of interest.
Source: Transfusion
DOI: 10.1111/trf.18047
Authors: Mark H. Yazer, Andrew Beckett, Evan M. Bloch, Andrew P. Cap, Claudia S. Cohn, Jennifer Gurney, Daniela Hermelin, Philip C. Spinella
Institutions: University of Pittsburgh, University of Toronto, Canadian Armed Forces, Johns Hopkins University, Johns Hopkins Medicine, Uniformed Services University of the Health Sciences, University of Minnesota, American Association of Blood Banks, Brooke Army Medical Center, Saint Louis University
Language: English
Subfield: Biochemistry
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4403489586